Taiko Pharmaceutical Co.,Ltd. (4574.T) Comparison with companies in other sectors?

Taiko Pharmaceutical Co.,Ltd. has a share price of 50.19M. You can analyze Taiko Pharmaceutical Co.,Ltd. (4574.T) competitors across different market sectors through stock heatmaps.

What are 4574.T's NET and operating margins?

Taiko Pharmaceutical Co.,Ltd. (4574.T) operating margin is around 0.10, and net profit margin is approximately 0.14 as of the latest reports.

In what way does 4574.T's earnings per share (EPS) trend reflect its financial momentum?

Taiko Pharmaceutical Co.,Ltd. (4574.T) EPS is -49.64 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Taiko Pharmaceutical Co.,Ltd. is -5.70, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Taiko Pharmaceutical Co.,Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Taiko Pharmaceutical Co.,Ltd. like P/E which is 15.82, P/B which is 1.78, and PEG which is 0.12. Compare them with sector averages to evaluate if the stock is priced fairly.

Taiko Pharmaceutical Co.,Ltd.

4574.T•JPX

Healthcare

Drug Manufacturers - Specialty & Generic

¥283.00

¥-1.00(-0.35%)

Taiko Pharmaceutical Co.,Ltd. (4574.T) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-49.64

P/E Ratio

-5.70

ROE

0.11%

Net Margin

0.14%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$14.20B

Shares OutstandingTotal number of shares issued

$50.19M

Book Value/ShareNet worth per share

$158.62

Revenue/ShareAnnual revenue per share

$125.35

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-49.64

Net MarginNet income as percentage of revenue

14.27%

Operating MarginOperating income as percentage of revenue

10.00%

ROEReturn on shareholders' equity

11.39%

ROAReturn on total assets

6.95%

ROCEReturn on capital employed

6.25%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

Cash/ShareCash and equivalents per share

$90.29

FCF YieldFree cash flow as percentage of market cap

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 4574.TFinancial Ratios Analysis details for 4574.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 4574.TSector Benchmarking details for 4574.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Taiko Pharmaceutical Co.,Ltd. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Taiko Pharmaceutical Co.,Ltd.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Taiko Pharmaceutical Co.,Ltd.'s unique business strengths and challenges.

Key Financial Metrics for Taiko Pharmaceutical Co.,Ltd.

For Taiko Pharmaceutical Co.,Ltd., essential financial indicators include EPS -49.64, PE -5.70, and ROE 0.11. These key ratios reveal insights into Taiko Pharmaceutical Co.,Ltd.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Taiko Pharmaceutical Co.,Ltd. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Taiko Pharmaceutical Co.,Ltd.

Metrics like Net Margin 14.27% and ROA 6.95% shed light on how well Taiko Pharmaceutical Co.,Ltd. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Taiko Pharmaceutical Co.,Ltd. can sustain its operations and continue growing in the future.

Valuation and Market Position of Taiko Pharmaceutical Co.,Ltd.

Using ratios such as P/B Ratio 1.78 and PEG Ratio 0.12, investors can assess whether Taiko Pharmaceutical Co.,Ltd. is appropriately valued based on its financials and growth potential. These figures, combined with Taiko Pharmaceutical Co.,Ltd.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Taiko Pharmaceutical Co.,Ltd.

Financial health indicators, such as Debt/Equity Ratio 0.25 and Cash Flow -, provide a snapshot of Taiko Pharmaceutical Co.,Ltd.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Taiko Pharmaceutical Co.,Ltd., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Taiko Pharmaceutical Co.,Ltd.

Investing in Taiko Pharmaceutical Co.,Ltd. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Taiko Pharmaceutical Co.,Ltd. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;